Clinical Trial Update: TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating TAC-PF with Avastin and photodynamic therapy for age-related macular degeneration was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• TAC-PF

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: TERMINATED